Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus

Pharmacotherapy

Volumn 35, Issue 4, 2015, Pages 424-432

  Gomes, Diane M ^a,b   Ward, Kristina E ^a   Laplante, Kerry L ^a,b,c  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Heterogeneous vancomycin intermediate Staphylococcus aureus; intermediate; methicillin resistant Staphylococcus aureus; minimum inhibitory concentration; reduced susceptibility; resistance; screening; Staphylococcus aureus; vancomycin; vancomycin intermediate Staphylococcus aureus

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTAROLINE; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; BLOOD CULTURE; CAREGIVER; COHORT ANALYSIS; DECISION MAKING; DRUG DOSE ESCALATION; DRUG MEGADOSE; HETERORESISTANT VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; MEDICAL STAFF; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PERSONAL HYGIENE; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS INFECTION; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; WOUND CARE; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECTS; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; LINEZOLID; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84927774814     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1577     Document Type: Article

References (70)

1. Dantes R, Mu Y, Belflower R, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013; 173: 1970-8.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
3. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
4. Jones RN,. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42 (Suppl 1): S13-24.
5. Hiramatsu K,. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55.
6. Casapao AM, Leonard SN, Davis SL, et al. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection. Antimicrob Agents Chemother 2013; [epub ahead of print].
7. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML,. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: 448-51.
8. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-8.
9. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
10. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC,. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
11. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML,. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
12. Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 2009; 53: 3447-52.
13. Leonard SN, Rybak MJ,. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. J Antimicrob Chemother 2009; 63: 155-60.
14. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G,. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-24.
15. Musta AC, Riederer K, Shemes S, et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009; 47: 1640-4.
16. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN,. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008; 46: 2950-4.
17. Satola SW, Farley MM, Anderson KF, Patel JB,. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol 2011; 49: 177-83.
18. van Hal SJ, Paterson DL,. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 405-10.
19. van Hal SJ, Wehrhahn MC, Barbagiannakos T, et al. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol 2011; 49: 1489-94.
20. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G,. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005; 56: 519-23.
21. Boyle-Vavra S, Berke SK, Lee JC, Daum RS,. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2000; 44: 272-7.
22. Richter SS, Diekema DJ, Heilmann KP, et al. Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States. Antimicrob Agents Chemother 2014; 58: 740-5.
23. Richter SS, Satola SW, Crispell EK, et al. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. J Clin Microbiol 2011; 49: 4203-7.
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. M100-S16. Wayne, PA: CLSI; 2006.
25. Tenover FC, Moellering RC Jr,. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44: 1208-15.
26. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP,. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403.
27. Leonard SN, Rossi KL, Newton KL, Rybak MJ,. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 2009; 63: 489-92.
28. Wootton M, MacGowan AP, Walsh TR, Howe RA,. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007; 45: 329-32.
29. Yusof A, Engelhardt A, Karlsson A, et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol 2008; 46: 3042-7.
30. Centers for Disease Control and Prevention. Laboratory detection of vancomycin-intermediate/resistant Staphylococcus aureus (VISA/VRSA). Available from http://www.cdc.gov/ncidod/dhqp/ar-visavrsa
31. Rybak MJ, Vidaillac C, Sader HS, et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol 2013; 51: 2077-81.
32. van Hal SJ, Lodise TP, Paterson DL,. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-71.
33. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK,. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50: 3039-47.
34. Cui L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41: 5-14.
35. Pfeltz RF, Singh VK, Schmidt JL, et al. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob Agents Chemother 2000; 44: 294-303.
36. Sakoulas G, Eliopoulos GM, Fowler VG Jr, et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005; 49: 2687-92.
37. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46: 1492-502.
38. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A,. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
39. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
40. Jacob JT, DiazGranados CA,. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis 2013; 17: e93-100.
41. Chen H, Liu Y, Sun W, Chen M, Wang H,. The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC. Diagn Microbiol Infect Dis 2011; 71: 301-3.
42. Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ,. Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2009; 53: 805-7.
43. Khatib R, Jose J, Musta A, et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011; 66: 1594-9.
44. Fong RK, Low J, Koh TH, Kurup A,. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 2009; 28: 983-7.
45. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36: 429-39.
46. Satola SW, Lessa FC, Ray SM, et al. Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. aureus phenotype. J Clin Microbiol 2011; 49: 1583-7.
47. Howden BP, Smith DJ, Mansell A, et al. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol 2008; 8: 39.
48. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM,. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-5.
49. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC,. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42: 1652-3.
50. Kelley PG, Gao W, Ward PB, Howden BP,. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011; 66: 1057-60.
51. Vidaillac C, Steed ME, Rybak MJ,. Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model. Antimicrob Agents Chemother 2011; 55: 2160-5.
52. Andrade-Baiocchi S, Tognim MC, Baiocchi OC, Sader HS,. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. Diagn Microbiol Infect Dis 2003; 45: 149-52.
53. Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR,. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 2008; 46: 1132-6.
54. Leung KT, Tong MK, Siu YP, Lam CS, Ng HL, Lee HK,. Treatment of vancomycin-intermediate Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2004; 36: 483-5.
55. Tenover FC, Sinner SW, Segal RE, et al. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int J Antimicrob Agents 2009; 33: 564-8.
56. Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV,. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 2011; 37: 558-61.
57. Saravolatz L, Pawlak J, Johnson L,. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010; 54: 3027-30.
58. Steed M, Vidaillac C, Rybak MJ,. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011; 55: 3522-6.
59. Vidaillac C, Leonard SN, Rybak MJ,. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009; 53: 4712-7.
60. Werth BJ, Steed ME, Kaatz GW, Rybak MJ,. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect." Antimicrob Agents Chemother 2013; 57: 2664-8.
61. Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007; 51: 3397-400.
62. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd,. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012; 67: 1267-70.
63. Werth BJ, Vidaillac C, Murray KP, et al. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother 2013; 57: 2376-9.
64. Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP,. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56: 202-7.
65. Dilworth TJ, Sliwinski J, Ryan K, Dodd M, Mercier RC,. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate Staphylococcus aureus isolates in vitro. Antimicrob Agents Chemother 2013; 58 (2): 1028-33.
66. Werth BJ, Barber KE, Ireland CE, Rybak MJ,. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother 2014; 58: 3177-81.
67. Avery LM, Steed ME, Woodruff AE, Hasan M, Rybak MJ,. Daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2012; 56: 5990-3.
68. Steed ME, Werth BJ, Ireland CE, Rybak MJ,. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother 2012; 56: 5709-14.
69. CDC reminds Clinical Laboratories and Healthcare infection preventionists of their role in the search and containment of vancomycin-resistant Staphylococcus aureus (VRSA). 2010. Available from http://www.cdc.gov/HAI/settings/lab/vrsa
70. Liu C, Chambers HF,. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47: 3040-5.